Cancel
Louise R. Rodino-Klapac, PhD
Executive Vice President, Head of R&D, Chief Scientific Officer
@
Sarepta Therapeutics
xf.8jj1quw143578.qg4@zxbbf58.uzj
Sign up to see email
Known information
- Renowned for her work in molecular genetics and gene therapy
- Pioneering research is the foundation for five investigational limb-girdle muscular dystrophy programs
- Leading the development of gene editing therapies at Sarepta's Gene Editing Innovation Center
- Collaborating with Charlie Gersbach, PhD, at the Gene Editing Innovation Center to develop gene editing therapies for Duchenne muscular dystrophy
About Sarepta Therapeutics
Sarepta Therapeutics is a biotechnology company specializing in precision genetic medicine for rare diseases, with over 40 investigational therapies and FDA-approved treatments for Duchenne muscular dystrophy.
Report inaccurate information
